Where 5 mg sits in treatment

The licensed start is 2.5 mg weekly for four weeks, then 5 mg weekly. Any further increases happen in stages when you need them. Whether you stay on 5 mg or move up later depends on the benefit, how well you tolerate the medicine and why you are being treated. Nobody has to reach the maximum.

Someone with type 2 diabetes reviews glucose results alongside weight. Someone else uses the medicine for obesity without diabetes. Their appointments measure success in different ways even when the pen shows the same strength.

What the SURMOUNT-1 results show

SURMOUNT-1 assigned adults with obesity, or overweight plus a weight-related complication, and without diabetes, to tirzepatide or placebo. The 5 mg group lost an average of 15.0% of body weight at 72 weeks in the treatment-regimen analysis, alongside lifestyle intervention. That figure is a trial average over a long period. It does not predict your first month at 5 mg.

People in the trial responded differently, and results depend on who was studied and how the data were analysed. If you stop treatment, miss doses or have other illnesses, your course may differ. The study shows 5 mg works as a treatment dose. No single amount of weight loss is guaranteed to any one person.

Hunger alone tells you little

Feeling hungry again before your next weekly injection does not mean 5 mg has stopped working. Hunger is a normal signal. Sleep, activity, menstrual cycles and what you eat all change it. Ask whether the overall pattern feels manageable and whether your health results are heading the right way.

You do not need to lose your appetite completely for treatment to succeed. If the dose makes eating enough hard, causes repeated vomiting or leaves you significantly weak, stronger appetite suppression is the wrong target. Report these effects to your prescriber. They are not a sign the medicine works better.

Deciding whether to stay or increase

A review compares several weeks of weight data, any relevant glucose readings, your nutrition and your side effects. Your prescriber should also ask whether your current result is worthwhile and sustainable. Staying on a stable maintenance dose spares you extra side effects when there is no clear need to go higher.

If your clinician recommends an increase, the label requires at least four weeks on your current dose before the next step. New symptoms, contraception needs or other medicines can change the plan. You should receive a clear prescription for the new strength. Never decide for yourself by counting clicks on a stronger pen.

Practical details of the 5 mg pen

The UK KwikPen gives four weekly doses at the strength printed on its label. Keep the instructions with the pen and check every delivery, especially after you change provider. A pen of another strength might look similar, and you still cannot swap one for the other.

Store the pen as the UK leaflet describes, including the time limit after first use and the temperature rules. If you miss more than a single dose, ask for a restart plan. Coping well on 5 mg in the past does not settle every question about starting again after a long break.

Sources

Your own medicine leaflet and prescriber come first. A source from another country does not mean the same rule applies in the UK.

  1. Mounjaro UK Summary of Product Characteristics, updated September 2026 medicines.org.uk
  2. Mounjaro UK patient information leaflet medicines.org.uk
  3. SURMOUNT-1: tirzepatide once weekly for obesity pubmed.ncbi.nlm.nih.gov
  4. NICE: prescribing, reviewing and stopping tirzepatide nice.org.uk

Spotted something out of date? Report a mistake.